Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

Clinical Trials

Clinical trial evaluates combination therapy for men with metastatic prostate cancer

Ravi A. Madan, M.D., Senior Clinician in the Genitourinary Malignancies Branch, is leading a study of an experimental treatment for men with two types of prostate cancer: one type that responds to hormone therapy and one that doesn’t.

Clinical trial studies immunotherapy combination for recurrent thymoma and thymic carcinoma

Thymic epithelial tumors (TETs) are rare cancers that originate from the cells of the thymus, a small organ that sits in the chest between the lungs and above the heart. Arun Rajan, M.D., Senior Clinician in the Thoracic and GI Malignancies Branch, is leading a clinical trial of a therapy for thymoma and thymic carcinoma that has returned after chemotherapy and cannot be treated with surgery.

Clinical trial studies therapy for relapsed/refractory T-cell malignancies

Milos Miljkovic, M.D., M.Sc., Assistant Research Physician in the Lymphoid Malignancies Branch, is leading a study of a 4-drug combination treatment strategy using romidepsin, oral 5-azacitidine, dexamethasone and lenalidomide for T-cell malignancies (TCMs). Researchers are seeking to determine the safety, side effects, and best dose of this 4-drug combination for people with relapsed/refractory TCM.

Study evaluates, treats, and follows patients with gastrointestinal stromal tumors

More than half of all gastrointestinal stromal tumors (GISTs) start in the stomach, but they can start anywhere in the GI tract. Andrew M. Blakely, M.D., Assistant Research Physician in the Surgical Oncology Program, is leading a study of GIST that could benefit current and future patients.

New clinical trial studies immunotherapy combination for metastatic breast cancer

Fatima Karzai, M.D., Associate Research Physician in the Genitourinary Malignancies Branch, is leading a study in adults with breast cancer that has spread to other places in the body. Researchers want to see if a combination of four drugs, which includes immunotherapy, can shrink the tumors of metastatic breast cancer.

Clinical trial studies therapy for adults with BRAF-mutant hairy cell leukemia

Adults with BRAF-mutant hairy cell leukemia, that did not respond to or came back after treatment, may be eligible to participate in a clinical trial at the NIH Clinical Center. Researchers want to see if combining encorafenib and binimetinib has an improved response rate than other drugs previously used to treat HCL.

Immunotherapy combination tested for advanced/metastatic solid tumors

Adults with locally advanced or metastatic solid tumors that cannot be treated with surgery may be eligible to participate in a clinical trial at the NIH Clinical Center. James L. Gulley, M.D., Ph.D., Chief of the Genitourinary Malignancies Branch, is leading a study exploring several different combinations of immunotherapies to see if they improve responses in people with cancer.

Analysis of T cells from melanoma patients uncovers characteristics leading to cancer regression

CCR researchers used state-ot-the-art analytic techniques to determine characteristics of cells used in effective adoptive T cell therapy (ACT) in patients with advanced melanoma. This new information opens the door to manufacturing these cells in the laboratory and using them in immunotherapy for common cancers, including liver, breast, prostate, and colon cancer.

Clinical trial evaluates therapy for adults with relapsed/refractory HCL

Robert J. Kreitman, M.D., Senior Investigator in the Laboratory of Molecular Biology, is leading a study of a treatment for hairy cell leukemia (HCL). The goal of this study is to determine the overall rate of response to binimetinib, an MEK inhibitor, in patients with HCL who do not have a BRAF gene mutation.

Treatment for women with advanced, untreated cervical cancer tested in new clinical trial

Women 18 and older with previously untreated advanced cervical cancer may be eligible to participate in a clinical trial at the NIH Clinical Center. Christian S. Hinrichs, M.D., Senior Investigator in the Genitourinary Malignancies Branch, is leading a study of a treatment called induction immunotherapy that uses the patient’s own T cells (immune cells) to attack their cancer cells.

Breadcrumb

Clinical Trials